{
    "id": "e320fe242f",
    "abstract": [],
    "body_text": [
        {
            "text": "Enteropathy-associated T-cell lymphoma (EATL) is a rare aggressive primary intestinal non-Hodgkin lymphoma accounting for 5.4% of peripheral T-cell lymphomas and 10-25% of all primary intestinal lymphomas. ",
            "section": "INTRODUCTION"
        },
        {
            "text": "[1][2][3] EATL was included into the World Health Organization classification of hematolymphoid neoplasms for the first time in 2008 and consists of type I and type II. ",
            "section": "INTRODUCTION"
        },
        {
            "text": "1 Classical or type I EATL is known to associate with celiac disease, HLA-DQ2 and DQ8 haplotypes, and is the more common form in the West. ",
            "section": "INTRODUCTION"
        },
        {
            "text": "1,2,[4][5][6][7][8] On the contrary, type II EATL is more prevalent in Asia and multiple studies have failed to confirm an association with celiac disease. ",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 31,
                    "end": 38,
                    "type": "table",
                    "text": "Table 8"
                }
            ],
            "entity_spans": [
                {
                    "start": 107,
                    "end": 113,
                    "type": "software",
                    "rawForm": "COSMIC",
                    "resp": "#annotator2",
                    "used": true,
                    "id": "e320fe242f-software-12"
                },
                {
                    "start": 116,
                    "end": 118,
                    "type": "version",
                    "rawForm": "72",
                    "resp": "#annotator2",
                    "id": "#e320fe242f-software-12"
                }
            ]
        },
        {
            "text": "[9][10][11][12] Given the distinct clinicopathological features of type II EATL as described below and the lack of association with celiac disease, the term 'enteropathy-associated' in its nomenclature is not appropriate and various names including monomorphic intestinal T-cell lymphoma 11 and epitheliotropic intestinal T-cell lymphoma (EITL) 13 have been proposed. ",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 122,
                    "end": 130,
                    "type": "figure",
                    "text": "Figure 2"
                },
                {
                    "start": 202,
                    "end": 213,
                    "type": "figure",
                    "text": "(Figure 2c)"
                }
            ]
        },
        {
            "text": "In this study, we will refer to this neoplasm as EITL henceforth.",
            "section": "INTRODUCTION"
        },
        {
            "text": "EITL has an extremely poor prognosis with a median overall survival of only 7 months. ",
            "section": "INTRODUCTION"
        },
        {
            "text": "13 No effective treatment or targeted therapies are currently available for this disease. ",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b12",
                    "text": "13"
                }
            ]
        },
        {
            "text": "A number of publications have focused on the clinical and pathological 1 Lymphoma Genomic Translational Research Laboratory, Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore; 2 Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, Singapore, Singapore; 3 Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, Singapore, Singapore; 4 Centre for Computational Biology, Duke-NUS Medical School, Singapore, Singapore; 5 Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore; 6 Department of Biomedical Engineering, Duke University, Durham, NC, USA; 7 Department of Pathology, Singapore General Hospital, Singapore, Singapore; 8 Advanced Molecular Pathology Laboratory, Singapore Health Services, Singapore, Singapore; 9 Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China; 10 Department of Pathology, Tan Tock Seng Hospital, Singapore, Singapore; 11 Department of Pathology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; 12 Department of Pathology, National University Hospital, National University Health System, Singapore, Singapore; 13 Department of Pathology, Chi Mei Medical Center, Tainan, Taiwan; 14 Department of Pathology, Taipei Medical University and National Taiwan University, Taipei, Taiwan; 15 Department of Pathology, Guangdong General Hospital, Guangzhou, China; 16 Department of Pathology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; characterization of EITL. ",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 211,
                    "end": 212,
                    "type": "bibr",
                    "ref_id": "b1",
                    "text": "2"
                },
                {
                    "start": 331,
                    "end": 332,
                    "type": "bibr",
                    "ref_id": "b2",
                    "text": "3"
                },
                {
                    "start": 421,
                    "end": 422,
                    "type": "bibr",
                    "ref_id": "b3",
                    "text": "4"
                },
                {
                    "start": 504,
                    "end": 505,
                    "type": "bibr",
                    "ref_id": "b4",
                    "text": "5"
                },
                {
                    "start": 601,
                    "end": 602,
                    "type": "bibr",
                    "ref_id": "b5",
                    "text": "6"
                },
                {
                    "start": 675,
                    "end": 676,
                    "type": "bibr",
                    "ref_id": "b6",
                    "text": "7"
                },
                {
                    "start": 752,
                    "end": 753,
                    "type": "bibr",
                    "ref_id": "b7",
                    "text": "8"
                },
                {
                    "start": 844,
                    "end": 845,
                    "type": "bibr",
                    "ref_id": "b8",
                    "text": "9"
                },
                {
                    "start": 927,
                    "end": 929,
                    "type": "bibr",
                    "ref_id": "b9",
                    "text": "10"
                },
                {
                    "start": 1001,
                    "end": 1003,
                    "type": "bibr",
                    "ref_id": "b10",
                    "text": "11"
                },
                {
                    "start": 1118,
                    "end": 1120,
                    "type": "bibr",
                    "ref_id": "b11",
                    "text": "12"
                },
                {
                    "start": 1233,
                    "end": 1235,
                    "type": "bibr",
                    "ref_id": "b12",
                    "text": "13"
                },
                {
                    "start": 1301,
                    "end": 1303,
                    "type": "bibr",
                    "ref_id": "b13",
                    "text": "14"
                },
                {
                    "start": 1403,
                    "end": 1405,
                    "type": "bibr",
                    "ref_id": "b14",
                    "text": "15"
                },
                {
                    "start": 1477,
                    "end": 1479,
                    "type": "bibr",
                    "ref_id": "b15",
                    "text": "16"
                }
            ]
        },
        {
            "text": "Together with others, we have comprehensively described the histology of this complex disease. ",
            "section": "INTRODUCTION"
        },
        {
            "text": "11,13 In short, EITL displays zonal variation featuring central invasive sheets of monomorphic neoplastic lymphocytes, a peripheral zone of mucosa infiltrated by morphologically atypical intraepithelial lymphocytes (IELs) and a distant zone featuring mucosa with normal villous architecture but increased number of morphologically normal IELs. ",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b10",
                    "text": "11,"
                },
                {
                    "start": 3,
                    "end": 5,
                    "type": "bibr",
                    "ref_id": "b12",
                    "text": "13"
                }
            ]
        },
        {
            "text": "The putative cell of origin is an intestinal IEL and clonality analyses have shown that the IELs in the distant mucosal zone share clonal relationship with the invasive lymphoma. ",
            "section": "INTRODUCTION"
        },
        {
            "text": "13,14 The CD8+ CD56+ phenotype and extensive nuclear expression of megakaryocyte-associated tyrosine kinase are features that are distinct from classical EATL, 13,15 with the majority of neoplastic cells expressing CD8\u03b1\u03b1 homodimers. ",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b12",
                    "text": "13,"
                },
                {
                    "start": 3,
                    "end": 5,
                    "type": "bibr",
                    "ref_id": "b13",
                    "text": "14"
                },
                {
                    "start": 160,
                    "end": 163,
                    "type": "bibr",
                    "ref_id": "b12",
                    "text": "13,"
                },
                {
                    "start": 163,
                    "end": 165,
                    "type": "bibr",
                    "ref_id": "b14",
                    "text": "15"
                }
            ]
        },
        {
            "text": "13 Opinion is still divided whether these cells display mainly T-cell receptor (TCR) \u03b1\u03b2 or \u03b3\u03b4 phenotypes. ",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b12",
                    "text": "13"
                }
            ]
        },
        {
            "text": "11,13 Cytogenetic studies have demonstrated gains and translocations of MYC (8q24) 10,13,16 in EITL, although they may also be seen in classical EATL. ",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b10",
                    "text": "11,"
                },
                {
                    "start": 3,
                    "end": 5,
                    "type": "bibr",
                    "ref_id": "b12",
                    "text": "13"
                },
                {
                    "start": 83,
                    "end": 86,
                    "type": "bibr",
                    "ref_id": "b9",
                    "text": "10,"
                },
                {
                    "start": 86,
                    "end": 89,
                    "type": "bibr",
                    "ref_id": "b12",
                    "text": "13,"
                },
                {
                    "start": 89,
                    "end": 91,
                    "type": "bibr",
                    "ref_id": "b15",
                    "text": "16"
                }
            ]
        },
        {
            "text": "17 Conversely, gains of 1q32.2-q41 and 5q34-q35.2 are more common in EATL compared with EITL, whereas 9q31.3 gain and 16q21.1 loss can be observed in both classical EATL and EITL. ",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b16",
                    "text": "17"
                }
            ]
        },
        {
            "text": "1,3 Recently, it was reported that an activating STAT5B p.N642H mutation is common in T-cell lymphoma derived from \u03b3\u03b4 T-cells, including some cases of EITL. ",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b0",
                    "text": "1,"
                },
                {
                    "start": 2,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b2",
                    "text": "3"
                }
            ]
        },
        {
            "text": "18 We used nextgeneration sequencing techniques in a multicenter study to describe the frequent genetic changes in EITL. ",
            "section": "INTRODUCTION",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b17",
                    "text": "18"
                }
            ]
        },
        {
            "text": "We provide here the first whole-exome sequencing (WES) study of this disease and, in the largest series published to date, demonstrate that STAT5Bactivating mutations are found in EITL tumors of both TCR\u03b1\u03b2 and TCR\u03b3\u03b4 origin. ",
            "section": "INTRODUCTION"
        },
        {
            "text": "We present multiple lines of evidence that JAK-STAT and G-protein-coupled receptor (GPCR) signaling pathways are highly activated in EITL, and, most importantly, inhibition of these pathways by targeted therapy effectively reduces the viability of primary EITL cells.",
            "section": "INTRODUCTION"
        },
        {
            "text": "EITL was defined as a primary intestinal T-cell lymphoma with characteristic morphology, typically with cytotoxic, CD3+ CD8+ CD56+ EBER \u2212 phenotype. ",
            "section": "Patients and samples"
        },
        {
            "text": "Five snap frozen primary tumors and matched whole blood samples were obtained from the SingHealth Tissue Repository. ",
            "section": "Patients and samples"
        },
        {
            "text": "The patients were recruited from 2010 to 2014 and all provided signed informed consent in accordance with the Declaration of Helsinki. ",
            "section": "Patients and samples"
        },
        {
            "text": "An additional 41 archival formalin-fixed paraffin-embedded samples collected from 2003 to 2014 were obtained from the following centers: National Cancer Centre Singapore, Singapore General Hospital, National University Hospital and Tan Tock Seng Hospital in Singapore, Guangdong General Hospital and Sun Yat-sen University Cancer Center in China, University of Malaya and Hospital Raja Permaisuri Bainun in Malaysia, Samsung Medical Centre in Korea, Chi Mei Medical Center in Taiwan and Mahidol University in Thailand. ",
            "section": "Patients and samples"
        },
        {
            "text": "Fourteen of those were also used in our previous study with the same identifiers. ",
            "section": "Patients and samples"
        },
        {
            "text": "13 Clinicopathological features are listed in Supplementary Table 1. ",
            "section": "Patients and samples",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b12",
                    "text": "13"
                },
                {
                    "start": 46,
                    "end": 67,
                    "type": "table",
                    "text": "Supplementary Table 1"
                }
            ]
        },
        {
            "text": "Tumor cell content was assessed by hematoxylin and eosin staining. ",
            "section": "Patients and samples"
        },
        {
            "text": "The study was approved by SingHealth Centralised Institutional Review Board (2004/407/F).",
            "section": "Patients and samples"
        },
        {
            "text": "Detailed methods are described in the Supplementary Information. ",
            "section": "Sequencing and mutation analysis"
        },
        {
            "text": "Briefly, four tumor-normal pairs of EITL were whole-exome sequenced using SureSelectXT Human All Exon V4+UTRs capture (Agilent Technologies, Santa Clara, CA, USA) and HiSeq 2000 Sequencing System (Illumina, San Diego, CA, USA). ",
            "section": "Sequencing and mutation analysis"
        },
        {
            "text": "All candidate variants were visually inspected in Integrative Genomics Viewer. ",
            "section": "Sequencing and mutation analysis"
        },
        {
            "text": "19,20 Only Integrative Genomics Viewer-true mutations were considered somatic and variants with frequency \u2a7e 15% were further validated by Sanger sequencing (Supplementary Table 2).",
            "section": "Sequencing and mutation analysis",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b18",
                    "text": "19,"
                },
                {
                    "start": 3,
                    "end": 5,
                    "type": "bibr",
                    "ref_id": "b19",
                    "text": "20"
                },
                {
                    "start": 171,
                    "end": 178,
                    "type": "table",
                    "text": "Table 2"
                }
            ]
        },
        {
            "text": "Prevalence screening was performed for GNAI2, JAK3 and STAT5B genes in 42 tumor samples using amplicon deep sequencing. ",
            "section": "Sequencing and mutation analysis"
        },
        {
            "text": "Only common hotspots reported in COSMIC v.72 and regions identified through WES were sequenced for each gene (Supplementary Table 3). ",
            "section": "Sequencing and mutation analysis",
            "ref_spans": [
                {
                    "start": 124,
                    "end": 131,
                    "type": "table",
                    "text": "Table 3"
                }
            ],
            "entity_spans": [
                {
                    "start": 33,
                    "end": 39,
                    "type": "software",
                    "rawForm": "COSMIC",
                    "resp": "#annotator2",
                    "used": true,
                    "id": "e320fe242f-software-7"
                },
                {
                    "start": 42,
                    "end": 44,
                    "type": "version",
                    "rawForm": "72",
                    "resp": "#annotator2",
                    "id": "#e320fe242f-software-7"
                }
            ]
        },
        {
            "text": "CREBBP mutation frequency was determined in a partial prevalence cohort (16 cases) using Single Primer Enrichment Technology (NuGEN Technologies, San Carlos, CA, USA). ",
            "section": "Sequencing and mutation analysis"
        },
        {
            "text": "SNP genotyping array and allele-specific copy number analysis of tumors Genomic DNA from four tumor-normal pairs was hybridized to GenomeWide Human Single-Nucleotide Polymorphism (SNP) Array 6.0 (Affymetrix, Santa Clara, CA, USA) chips. ",
            "section": "Sequencing and mutation analysis"
        },
        {
            "text": "Allele-specific copy number analysis of tumors was performed as described previously. ",
            "section": "Sequencing and mutation analysis"
        },
        {
            "text": "21 Stable cell line construction and western blot Full-length GNAI2 cDNA was amplified using AccuPrime Pfx DNA Polymerase (Invitrogen, Carlsbad, CA, USA) and cloned into retroviral vector MIGR1 (Addgene; plasmid no. 27490) 22 at XhoI and EcoRI sites.Ex vivo cell viability assay in primary EITL cells Primary EITL cells from patient 065T were subcutaneously injected into the NOD scid gamma (NSG) mouse (P1; The Jackson Laboratory, Bar Harbor, ME, USA), followed by further passaging of the subcutaneously formed tumor cells by subcutaneous and intraperitoneal injection (P2). ",
            "section": "Sequencing and mutation analysis",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "text": "21"
                },
                {
                    "start": 223,
                    "end": 225,
                    "type": "bibr",
                    "text": "22"
                }
            ]
        },
        {
            "text": "Eight-weekold female animals were used in each passage. ",
            "section": "Sequencing and mutation analysis"
        },
        {
            "text": "P2 mouse presented with highly swollen peritoneum, and intestinal and peritoneal tumors. ",
            "section": "Sequencing and mutation analysis"
        },
        {
            "text": "All samples, including peritoneal fluid cells from P2, were histologically characterized by a senior hematopathologist (SYT) and diagnosed EITL. ",
            "section": "Sequencing and mutation analysis"
        },
        {
            "text": "Owing to the consistent phenotype between patient's primary tumor and P2 peritoneal fluid cells, we will refer to the latter as primary EITL cells henceforth. ",
            "section": "Sequencing and mutation analysis"
        },
        {
            "text": "Sanger sequencing confirmed the presence of all somatic mutations identified in the original tumor (Supplementary Table 5) also in the primary cells. ",
            "section": "Sequencing and mutation analysis",
            "ref_spans": [
                {
                    "start": 114,
                    "end": 121,
                    "type": "table",
                    "text": "Table 5"
                }
            ]
        },
        {
            "text": "Animal experiments were in compliance with ethical regulations of the SingHealth Institutional Animal Care and Use Committee.",
            "section": "Sequencing and mutation analysis"
        },
        {
            "text": "Genomic DNA from four tumor-normal pairs was hybridized to Genome-Wide Human Single-Nucleotide Polymorphism (SNP) Array 6.0 (Affymetrix, Santa Clara, CA, USA) chips. ",
            "section": "SNP genotyping array and allele-specific copy number analysis of tumors"
        },
        {
            "text": "Allele-specific copy number analysis of tumors was performed as described previously. ",
            "section": "SNP genotyping array and allele-specific copy number analysis of tumors"
        },
        {
            "text": "21 ",
            "section": "SNP genotyping array and allele-specific copy number analysis of tumors",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b20",
                    "text": "21"
                }
            ]
        },
        {
            "text": "Full-length GNAI2 cDNA was amplified using AccuPrime Pfx DNA Polymerase (Invitrogen, Carlsbad, CA, USA) and cloned into retroviral vector MIGR1 (Addgene; plasmid no. 27490) 22 at XhoI and EcoRI sites. ",
            "section": "Stable cell line construction and western blot",
            "ref_spans": [
                {
                    "start": 173,
                    "end": 175,
                    "type": "bibr",
                    "ref_id": "b21",
                    "text": "22"
                }
            ]
        },
        {
            "text": "GNAI2 mutations (c.535C4T for p.R179C and c.535C4A for p.R179S) were generated by QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) and confirmed by Sanger sequencing.",
            "section": "Stable cell line construction and western blot"
        },
        {
            "text": "HuT78 and Jurkat cell lines were from ATCC (Manassas, VA, USA) and maintained in Iscove's modified Dulbecco's medium (Invitrogen) supplemented with 20% fetal bovine serum (HyClone; GE Healthcare, Little Chalfont, UK) and RPMI-1640 (Invitrogen) supplemented with 10% fetal bovine serum (HyClone; GE Healthcare), respectively. ",
            "section": "Stable cell line construction and western blot"
        },
        {
            "text": "The cultures were routinely checked for mycoplasma contamination. ",
            "section": "Stable cell line construction and western blot"
        },
        {
            "text": "Stable cell lines were generated by retroviral infection and sorting of green fluorescent proteinpositive cells using BD FACSAria III Cell Sorter (BD Biosciences, Franklin Lakes, NJ, USA).",
            "section": "Stable cell line construction and western blot"
        },
        {
            "text": "Protein extracts were prepared in RIPA cell lysis buffer (150 mM NaCl, 50 mM Tris-HCl, 0.5% deoxychlorate sodium, 200 mM NaF, 200 mM PMSF, 1% NP-40 and 1 mM EDTA) in the presence of freshly added protease inhibitor (Roche, Basel, Switzerland). ",
            "section": "Stable cell line construction and western blot"
        },
        {
            "text": "HuT78 lines underwent serum starvation for 24 h before collection of protein lysates. ",
            "section": "Stable cell line construction and western blot"
        },
        {
            "text": "Total protein extracts were separated on sodium dodecyl sulfate-polyacrylamide gel and transferred to Trans-Blot Turbo Mini PVDF membranes (Bio-Rad, Hercules, CA, USA). ",
            "section": "Stable cell line construction and western blot"
        },
        {
            "text": "The used antibodies are listed in Supplementary Table 4. ",
            "section": "Stable cell line construction and western blot",
            "ref_spans": [
                {
                    "start": 34,
                    "end": 55,
                    "type": "table",
                    "text": "Supplementary Table 4"
                }
            ]
        },
        {
            "text": "Signals were visualized using ChemiDoc MP System (Bio-Rad).",
            "section": "Stable cell line construction and western blot"
        },
        {
            "text": "Primary EITL cells from patient 065T were subcutaneously injected into the NOD scid gamma (NSG) mouse (P1; The Jackson Laboratory, Bar Harbor, ME, USA), followed by further passaging of the subcutaneously formed tumor cells by subcutaneous and intraperitoneal injection (P2). ",
            "section": "Ex vivo cell viability assay in primary EITL cells"
        },
        {
            "text": "Eight-weekold female animals were used in each passage. ",
            "section": "Ex vivo cell viability assay in primary EITL cells"
        },
        {
            "text": "P2 mouse presented with highly swollen peritoneum, and intestinal and peritoneal tumors. ",
            "section": "Ex vivo cell viability assay in primary EITL cells"
        },
        {
            "text": "All samples, including peritoneal fluid cells from P2, were histologically characterized by a senior hematopathologist (SYT) and diagnosed EITL. ",
            "section": "Ex vivo cell viability assay in primary EITL cells"
        },
        {
            "text": "Owing to the consistent phenotype between patient's primary tumor and P2 peritoneal fluid cells, we will refer to the latter as primary EITL cells henceforth. ",
            "section": "Ex vivo cell viability assay in primary EITL cells"
        },
        {
            "text": "Sanger sequencing confirmed the presence of all somatic mutations identified in the original tumor (Supplementary Table 5) also in the primary cells. ",
            "section": "Ex vivo cell viability assay in primary EITL cells",
            "ref_spans": [
                {
                    "start": 114,
                    "end": 121,
                    "type": "table",
                    "text": "Table 5"
                }
            ]
        },
        {
            "text": "Animal experiments were in compliance with ethical regulations of the SingHealth Institutional Animal Care and Use Committee.",
            "section": "Ex vivo cell viability assay in primary EITL cells"
        },
        {
            "text": "Primary EITL cells were maintained in RPMI-1640 (Invitrogen) supplemented with 10% human serum (Sigma-Aldrich, St Louis, MO, USA) and 500 IU/ml interleukin-2 (Miltenyi Biotec, Bergisch Gladbach, Germany). ",
            "section": "Ex vivo cell viability assay in primary EITL cells"
        },
        {
            "text": "To test the feasibility of targeted therapy in EITL, 5 \u00d7 10 3 cells were seeded in 96-well plates in three technical replicates and treated with Stattic (CAS 19983-44-9; Selleck Chemicals, Houston, TX, USA) and MEK inhibitor PD0325901 (CAS 391210-10-9; Axon Medchem, Groningen, The Netherlands) for 72 h, and Tofacitinib (CP 690550; Selleck Chemicals), Trametinib (GSK 1120212; Axon Medchem) and Gefitinib (ZD 1839; Axon Medchem) for 96 h at indicated concentrations. ",
            "section": "Ex vivo cell viability assay in primary EITL cells"
        },
        {
            "text": "Cell viability was measured using the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI, USA). ",
            "section": "Ex vivo cell viability assay in primary EITL cells"
        },
        {
            "text": "The efficacy of inhibitors was further evaluated by their effect on downstream targets using western blot. ",
            "section": "Ex vivo cell viability assay in primary EITL cells"
        },
        {
            "text": "Cell lysates for PD0325901, Trametinib and Tofacitinib were collected 2 h and for Stattic 24 h posttreatment. ",
            "section": "Ex vivo cell viability assay in primary EITL cells"
        },
        {
            "text": "Dose-response curves were plotted using the Prism software (GraphPad, La Jolla, CA, USA). ",
            "section": "Ex vivo cell viability assay in primary EITL cells"
        },
        {
            "text": "All drug treatment experiments were repeated at least two times with each inhibitor.",
            "section": "Ex vivo cell viability assay in primary EITL cells"
        },
        {
            "text": "Sequencing data from WES, Single Primer Enrichment Technology and amplicon deep sequencing has been deposited in the European Nucleotide Archive with the accession number PRJEB9720. ",
            "section": "Accession numbers"
        },
        {
            "text": "The Affymetrix Genome-Wide Human SNP Array 6.0 and GeneChip Human Genome U133 Plus 2.0 Array data are available in the Gene Expression Omnibus 23 with the accession number GSE70654.",
            "section": "Accession numbers",
            "ref_spans": [
                {
                    "start": 143,
                    "end": 145,
                    "type": "bibr",
                    "ref_id": "b22",
                    "text": "23"
                }
            ]
        },
        {
            "text": "Identification of somatic variants by WES To identify somatic mutations in EITL, we performed WES of four tumors with matching whole blood samples (Figure 1a). ",
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 147,
                    "end": 157,
                    "type": "figure",
                    "ref_id": "fig_0",
                    "text": "(Figure 1a"
                }
            ]
        },
        {
            "text": "To maximize variant detection from a limited sample size, three different variant callers were applied-Genome Analysis Toolkit, 24 MuTect 25 and Strelka. ",
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 128,
                    "end": 130,
                    "type": "bibr",
                    "ref_id": "b23",
                    "text": "24"
                },
                {
                    "start": 138,
                    "end": 140,
                    "type": "bibr",
                    "ref_id": "b24",
                    "text": "25"
                }
            ]
        },
        {
            "text": "26 The mean depth of coverage was 126 \u00d7 and on average 88% of targeted bases were covered by at least 20 reads (Supplementary Table 6). ",
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b25",
                    "text": "26"
                },
                {
                    "start": 126,
                    "end": 133,
                    "type": "table",
                    "text": "Table 6"
                }
            ]
        },
        {
            "text": "Sanger validation of 296 candidate variants showed a false-positive rate of 3.72%. ",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "EITL samples presented a high mutation burden with an average of 85 mutations per sample (range 59-137). ",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "A total of 340 nonsynonymous somatic mutations were identified in 313 genes. ",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Seven of those genes also harbored silent somatic mutations (Supplementary Table 5). ",
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 75,
                    "end": 82,
                    "type": "table",
                    "text": "Table 5"
                }
            ]
        },
        {
            "text": "Among those were the calcium ionbinding gene multiple EGF-like-domains 6 (MEGF6), regulator of cell size proline-rich 16 (PRR16) and the giant muscle protein Titin (TTN), genes with functions in neuronal migration, axon guidance and chemoattraction-Reelin (RELN), Roundabout 1 (ROBO1) and Semaphorin 3 A (SEMA3A)-and with functions in the movement and transportation of cilia-Dynein 9 (DNAH9) and Intraflagellar Transport 140 (IFT140). ",
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 174,
                    "end": 198,
                    "type": "figure",
                    "ref_id": "fig_0",
                    "text": "Supplementary Figure 1a)"
                },
                {
                    "start": 235,
                    "end": 238,
                    "type": "bibr",
                    "ref_id": "b26",
                    "text": "27,"
                },
                {
                    "start": 238,
                    "end": 240,
                    "type": "bibr",
                    "ref_id": "b27",
                    "text": "28"
                },
                {
                    "start": 323,
                    "end": 347,
                    "type": "figure",
                    "ref_id": "fig_0",
                    "text": "Supplementary Figure 1b)"
                }
            ]
        },
        {
            "text": "In addition, mutations were identified in the histone acetyltransferase CREB-binding protein (CREBBP) and two (putative) histone methyltransferases-additional sex comblike transcriptional regulator 3 (ASXL3) and SET domain-containing 2 (SETD2)-suggesting that epigenetic dysregulation may have a role in EITL.",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "A total of 14 genes were found recurrently mutated (Figure 1b  and Supplementary Table 5). ",
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 51,
                    "end": 88,
                    "type": "table",
                    "text": "(Figure 1b  and Supplementary Table 5"
                }
            ]
        },
        {
            "text": "Among those were the calcium ionbinding gene multiple EGF-like-domains 6 (MEGF6), regulator of cell size proline-rich 16 (PRR16) and the giant muscle protein Titin (TTN), genes with functions in neuronal migration, axon guidance and chemoattraction-Reelin (RELN), Roundabout 1 (ROBO1) and Semaphorin 3 A (SEMA3A)-and with functions in the movement and transportation of cilia-Dynein 9 (DNAH9) and Intraflagellar Transport 140 (IFT140). ",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "In addition, mutations were identified in the histone acetyltransferase CREB-binding protein (CREBBP) and two (putative) histone methyltransferases-additional sex comblike transcriptional regulator 3 (ASXL3) and SET domain-containing 2 (SETD2)-suggesting that epigenetic dysregulation may have a role in EITL.",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Interestingly, three of the recurrently mutated genes presented with known activating hotspot variants. ",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "These included two key members of the JAK-STAT pathway, a central signaling cascade in immune cells-janus kinase 3 (JAK3) and signal transducer and activator of transcription 5B (STAT5B)-and G protein alpha inhibiting activity polypeptide 2 (GNAI2), a member of the family of G\u03b1 proteins. ",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Remarkably, STAT5B was mutated in all four cases, suggesting a critical role in EITL formation. ",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Three samples possessed the common p.N642H mutation, whereas the fourth harbored a complex substitution event in the beginning of exon 17, resulting in two amino-acid changes-p.V712E and p.S715L (see Supplementary Note and Supplementary Figure 2). ",
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 223,
                    "end": 245,
                    "type": "figure",
                    "text": "Supplementary Figure 2"
                }
            ]
        },
        {
            "text": "Both JAK3 and GNAI2 were mutated in a remarkable 2/4 cases. ",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "JAK3 alterations occurred at two distinct activating positions (p.V674A and p.M511I), whereas GNAI2 was mutated in the same codon in both samples (p.R179C and p.R179S).",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "To understand the clonal architecture of EITL tumors, we used SciClone 29 to identify populations of cells containing specific mutations. ",
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 71,
                    "end": 73,
                    "type": "bibr",
                    "ref_id": "b28",
                    "text": "29"
                }
            ]
        },
        {
            "text": "All four discovery cohort samples demonstrated notable intratumor heterogeneity with five subclones present in each tumor sample ( Figure 1c, Supplementary Figure 3 and Supplementary Table 7). ",
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 131,
                    "end": 140,
                    "type": "figure",
                    "ref_id": "fig_0",
                    "text": "Figure 1c"
                },
                {
                    "start": 142,
                    "end": 164,
                    "type": "figure",
                    "ref_id": "fig_1",
                    "text": "Supplementary Figure 3"
                },
                {
                    "start": 169,
                    "end": 190,
                    "type": "table",
                    "text": "Supplementary Table 7"
                }
            ]
        },
        {
            "text": "As only copy-neutral loss of heterozygosity-free segments were analyzed, we were not able to determine whether the JAK3 and STAT5B mutations were located in different subclones. ",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "However, respective corrected variant allele frequencies do indicate that these mutations are located within two separate clones (Supplementary Table 5).",
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 144,
                    "end": 151,
                    "type": "table",
                    "text": "Table 5"
                }
            ]
        },
        {
            "text": "Prevalence screening of GNAI2, JAK3, STAT5B and CREBBP The high frequency of STAT5B, JAK3 and GNAI2 mutations in a small discovery cohort of only four samples was intriguing, prompting us to further analyze the prevalence of these mutations in a larger series of EITL samples. ",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Forty-two additional EITL tumors (1 snap frozen and 41 archival samples) were screened for GNAI2, JAK3 and STAT5B mutations using amplicon deep sequencing. ",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "A total of 57 identified mutations were covered by an average of 20 004 reads (range 104-175 515; Supplementary Table 8). ",
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 98,
                    "end": 119,
                    "type": "figure",
                    "text": "Supplementary Table 8"
                }
            ]
        },
        {
            "text": "As the amplicons covered only common mutation hotspots reported inCOSMIC v.72 and positions identified in the discovery cohort, it is likely that our results are lower-bound estimates of the true mutation frequency of these three genes. ",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Figure 2 summarizes the results from both the discovery and prevalence cohorts. ",
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 1,
                    "end": 9,
                    "type": "figure",
                    "text": "Figure 2"
                }
            ]
        },
        {
            "text": "(Figure 2c). ",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "We identified two samples carrying two separate JAK3-activating mutations and a remarkable three activating mutations were identified in a third case indicating profound alteration of JAK3 function in these patients. ",
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 146,
                    "end": 156,
                    "type": "figure",
                    "text": "(Figure 2b"
                }
            ]
        },
        {
            "text": "Notably, none of these samples contained an activating STAT5B mutation (Figure 2a). ",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Collectively, the JAK-STAT pathway was altered in 32/42 (76%) cases. ",
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 28,
                    "end": 38,
                    "type": "figure",
                    "text": "(Figure 2c"
                }
            ]
        },
        {
            "text": "It is remarkable that a large subset of tumors harbor co-occurring activating mutations in two members of the same pathway. ",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "A similar phenomenon was recently described for JAK1 and STAT3 in systemic ALK-negative anaplastic large T-cell lymphomas. ",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "30 Moreover, these mutants were demonstrated to act in synergy to constitutively activate downstream STAT3 signaling. ",
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 12,
                    "end": 23,
                    "type": "figure",
                    "text": "(Figure 2a)"
                }
            ]
        },
        {
            "text": "Further studies for mutated JAK3 and STAT5B are thus warranted and might shed light on EITL tumorigenesis. ",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "GNAI2 mutations were observed in 9/42 (21%) samples. ",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Two major hotspots were identified-p.R179 and p.T182-both located in the GTP-binding domain (Figure 2d) and are known activating variants. ",
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 63,
                    "end": 65,
                    "type": "bibr",
                    "ref_id": "b29",
                    "text": "30"
                }
            ]
        },
        {
            "text": "31-33 A single case was found to contain both mutations. ",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Although exhibiting a lower mutation incidence compared with STAT5B and JAK3, it has been suggested that the lower frequencies for G protein \u03b1-subunits could be explained by mutations in receptors coupled to these G proteins. ",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "34 On that note, both the GNAI2 wild-type discovery cohort samples harbored somatic mutations in GPCRs (Supplementary Table 5). ",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "It would be therefore interesting to analyze the mutational prevalence of GPCRs and other members of G\u03b1 i signaling in a larger cohort to determine the frequency at which this cascade is altered in EITL.",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "GNAI2 mutations were observed in 9/42 (21%) samples. ",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Two major hotspots were identified-p.R179 and p.T182-both located in the GTP-binding domain (Figure 2d) and are known activating variants. ",
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 92,
                    "end": 102,
                    "type": "figure",
                    "text": "(Figure 2d"
                }
            ]
        },
        {
            "text": "[31][32][33] A single case was found to contain both mutations. ",
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 4,
                    "type": "bibr",
                    "ref_id": "b30",
                    "text": "[31]"
                },
                {
                    "start": 4,
                    "end": 8,
                    "type": "bibr",
                    "ref_id": "b31",
                    "text": "[32]"
                },
                {
                    "start": 8,
                    "end": 12,
                    "type": "bibr",
                    "ref_id": "b32",
                    "text": "[33]"
                }
            ]
        },
        {
            "text": "Although exhibiting a lower mutation incidence compared with STAT5B and JAK3, it has been suggested that the lower frequencies for G protein \u03b1-subunits could be explained by mutations in receptors coupled to these G proteins. ",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "34 On that note, both the GNAI2 wild-type discovery cohort samples harbored somatic mutations in GPCRs (Supplementary Table 5). ",
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b33",
                    "text": "34"
                },
                {
                    "start": 118,
                    "end": 125,
                    "type": "table",
                    "text": "Table 5"
                }
            ]
        },
        {
            "text": "It would be therefore interesting to analyze the mutational prevalence of GPCRs and other members of G\u03b1 i signaling in a larger cohort to determine the frequency at which this cascade is altered in EITL.",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Alterations in all three genes were found to be not mutually exclusive (JAK3 vs STAT5B: P-value = 0.2527; GNAI2 vs STAT5B: P-value = 0.5118; GNAI2 vs JAK3: P-value = 0.9998; one-sided Fisher's exact test by CoMEt 35 ). ",
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 213,
                    "end": 215,
                    "type": "bibr",
                    "ref_id": "b34",
                    "text": "35"
                }
            ]
        },
        {
            "text": "Owing to the limited number of events, we were not able to analyze the subclonality of amplicon deep sequencing data; however, corrected variant allele frequencies do suggest that multiple mutations in all three genes can be found both within the same as well as different subclones (Supplementary Table 8).",
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 298,
                    "end": 305,
                    "type": "table",
                    "text": "Table 8"
                }
            ]
        },
        {
            "text": "We also analyzed the mutation frequency of CREBBP in a partial prevalence cohort of 16 samples. ",
            "section": "RESULTS AND DISCUSSION"
        },
        {
            "text": "Mutations were identified in 2/16 (13%) cases, and in total, CREBBP was mutated in 6/20 (30%) samples ( Supplementary Figure 4 and Supplementary Table 9). ",
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 104,
                    "end": 126,
                    "type": "figure",
                    "ref_id": "fig_2",
                    "text": "Supplementary Figure 4"
                },
                {
                    "start": 131,
                    "end": 152,
                    "type": "table",
                    "text": "Supplementary Table 9"
                }
            ]
        },
        {
            "text": "Inactivating CREBBP mutations have been reported in a number of malignancies, including B-cell lymphomas, 36,37 and the mutations have been described as early events associated with inferior outcome. ",
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 106,
                    "end": 109,
                    "type": "bibr",
                    "ref_id": "b35",
                    "text": "36,"
                },
                {
                    "start": 109,
                    "end": 111,
                    "type": "bibr",
                    "ref_id": "b36",
                    "text": "37"
                }
            ]
        },
        {
            "text": "38,39 Although in our series each identified variant was predicted to be disruptive, all mutations occurred in samples with coinciding STAT5B and/or JAK3 mutations, suggesting that CREBBP mutations might not be the major initiating event and further support the importance of activated JAK-STAT pathway in EITL.",
            "section": "RESULTS AND DISCUSSION",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b37",
                    "text": "38,"
                },
                {
                    "start": 3,
                    "end": 5,
                    "type": "bibr",
                    "ref_id": "b38",
                    "text": "39"
                }
            ]
        },
        {
            "text": "The identified STAT5B mutation frequency is nearly twice that of a previously published study of EITLs with TCR\u03b3\u03b4 expression. ",
            "section": "Correlation of mutations with pathological features"
        },
        {
            "text": "18 As the latter relied on Sanger sequencing, this difference may at least, in part, be explained by the lower sensitivity of Sanger sequencing. ",
            "section": "Correlation of mutations with pathological features",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b17",
                    "text": "18"
                }
            ]
        },
        {
            "text": "However, our observations do not support the hypothesis that STAT5B-activating mutations only occur in the TCR\u03b3\u03b4 lineage of EITLs as activating variants were equally identified in TCR\u03b1\u03b2, TCR\u03b3\u03b4, double-negative and aberrant double-positive cases (20%, 36%, 32% and 12% in each subset, respectively; Figure 2a and Supplementary Table 10). ",
            "section": "Correlation of mutations with pathological features",
            "ref_spans": [
                {
                    "start": 298,
                    "end": 307,
                    "type": "figure",
                    "text": "Figure 2a"
                },
                {
                    "start": 312,
                    "end": 334,
                    "type": "table",
                    "text": "Supplementary Table 10"
                }
            ]
        },
        {
            "text": "A similar observation was also made for the JAK3-and GNAI2-activating mutations.",
            "section": "Correlation of mutations with pathological features"
        },
        {
            "text": "We further segregated the samples by the expression of CD8 dimer. ",
            "section": "Correlation of mutations with pathological features"
        },
        {
            "text": "Activating mutations of each gene were present in tumors with CD8\u03b1\u03b1, CD8\u03b1\u03b2 and double-negative T-cells, with more than half of samples with STAT5B-activating variants being of the CD8\u03b1\u03b1 type (61% CD8\u03b1\u03b1, 26% CD8\u03b1\u03b2 and 13% double negative; Supplementary Table 10). ",
            "section": "Correlation of mutations with pathological features",
            "ref_spans": [
                {
                    "start": 238,
                    "end": 260,
                    "type": "table",
                    "text": "Supplementary Table 10"
                }
            ]
        },
        {
            "text": "This is consistent with the notion that EITL is predominantly a tumor of CD8\u03b1\u03b1 IELs. ",
            "section": "Correlation of mutations with pathological features"
        },
        {
            "text": "13 Importantly, there is no phenotypic variation between the mutant cases with different TCR and/or CD8 expression ( Supplementary Figures 5  and 6).",
            "section": "Correlation of mutations with pathological features",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b12",
                    "text": "13"
                },
                {
                    "start": 117,
                    "end": 147,
                    "type": "figure",
                    "text": "Supplementary Figures 5  and 6"
                }
            ]
        },
        {
            "text": "To characterize the chromosomal abnormalities in EITL, we profiled all samples from the discovery cohort on a genomewide SNP array. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "All tumors were approximately diploid. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "We identified each of the previously reported frequent chromosomal change (loss of 16q12.1 and gains of 9q31.3 and 8q24) 1,3,10,13 recurrently altered in 2/4 samples (Supplementary Table 11). ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 121,
                    "end": 123,
                    "type": "bibr",
                    "ref_id": "b0",
                    "text": "1,"
                },
                {
                    "start": 123,
                    "end": 125,
                    "type": "bibr",
                    "ref_id": "b2",
                    "text": "3,"
                },
                {
                    "start": 125,
                    "end": 128,
                    "type": "bibr",
                    "ref_id": "b9",
                    "text": "10,"
                },
                {
                    "start": 128,
                    "end": 130,
                    "type": "bibr",
                    "ref_id": "b12",
                    "text": "13"
                },
                {
                    "start": 181,
                    "end": 189,
                    "type": "table",
                    "text": "Table 11"
                }
            ]
        },
        {
            "text": "This includes amplification of the MYC gene (four copies in two samples). ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "Importantly, no gains of 1q32.2-q41 and 5q34-q35.5, alterations more common in classical EATL compared with EITL, were identified. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "Other recurrent losses included 8p, 11q and 12p, and gain of 7q (detailed regions in Supplementary Table 11).",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 85,
                    "end": 108,
                    "type": "table",
                    "text": "Supplementary Table 11)"
                }
            ]
        },
        {
            "text": "Remarkably, all four samples demonstrated copy-neutral loss of heterozygosity at chromosome 17q where STAT5B is located (Figures 3a and b). ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 120,
                    "end": 138,
                    "type": "figure",
                    "ref_id": "fig_1",
                    "text": "(Figures 3a and b)"
                }
            ]
        },
        {
            "text": "This phenomenon has previously been observed in JAK2 and JAK3 in other hematological neoplasms, 40,41 and is thought to arise from somatic recombination events. ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 96,
                    "end": 99,
                    "type": "bibr",
                    "ref_id": "b39",
                    "text": "40,"
                },
                {
                    "start": 99,
                    "end": 101,
                    "type": "bibr",
                    "ref_id": "b40",
                    "text": "41"
                }
            ]
        },
        {
            "text": "To the best of our knowledge, this is the first time acquired uniparental disomy has been described for STAT5B and further indicates the pivotal role played by this gene in the development of EITL. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "Consistent with this, immunohistochemical analysis of samples with mutated STAT5B revealed noticeable upregulation of phosphorylated STAT5 (Supplementary Table 12), an example of which is shown in Figure 3c. ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 139,
                    "end": 162,
                    "type": "table",
                    "text": "(Supplementary Table 12"
                },
                {
                    "start": 197,
                    "end": 206,
                    "type": "figure",
                    "ref_id": "fig_1",
                    "text": "Figure 3c"
                }
            ]
        },
        {
            "text": "It would be interesting to see whether there exists a transition from heterozygosity to homozygosity either histologically from distant mucosa to central tumor zone or clinically from primary diagnosis to relapse representing clonal evolution as observed in other tumors. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "41,42 We also identified two samples with amplification of the PIK3CG gene (five and four copies, respectively) that was also evident on protein level both for PIK3CG itself and downstream pAKT in one sample (Supplementary Figure 7). ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 3,
                    "type": "bibr",
                    "ref_id": "b40",
                    "text": "41,"
                },
                {
                    "start": 3,
                    "end": 5,
                    "type": "bibr",
                    "ref_id": "b41",
                    "text": "42"
                },
                {
                    "start": 208,
                    "end": 232,
                    "type": "figure",
                    "text": "(Supplementary Figure 7)"
                }
            ]
        },
        {
            "text": "The prevalence of such amplification should be studied in a larger cohort as it might open up novel possibilities for targeted therapy. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "The first PI3K inhibitor is already in use for treatment of certain B-cell malignancies with many more currently in development. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "43 Pathways and biological functions affected in EITL To identify key biological functions and signaling pathways affected in EITL, two different approaches were used-Ingenuity Pathway Analysis (IPA) of mutated genes from WES and Gene Set Enrichment Analysis (GSEA) following gene expression profiling of EITL tumors.",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b42",
                    "text": "43"
                }
            ]
        },
        {
            "text": "Among all mutated genes, major cellular functions such as cell death, survival, development, differentiation, homeostasis and proliferation were found significantly enriched (Supplementary Table 13), many of these affecting lymphocytes or T-cells specifically. ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 189,
                    "end": 197,
                    "type": "table",
                    "text": "Table 13"
                }
            ]
        },
        {
            "text": "In addition, mutated genes were also significantly associated with components involved in T-cell and intestine morphology and genes known to be involved in cancer and lymphoid malignancies. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "Importantly, enrichment of cell signaling and binding of DNA were also noted. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "All these suggest that key cellular functions are involved in the development of EITL and correlate well with the nature of this disease.",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "Further supporting our genomic findings, canonical JAK-STAT and GPCR signaling were among the top-enriched IPA pathways (false discovery rate q-value = 0.24 and 0.03, respectively; Supplementary Table 14). ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 195,
                    "end": 203,
                    "type": "table",
                    "text": "Table 14"
                }
            ]
        },
        {
            "text": "In addition, several other aspects of Figure 2. ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 38,
                    "end": 46,
                    "type": "figure",
                    "text": "Figure 2"
                }
            ]
        },
        {
            "text": "Frequently mutated genes in EITL identified by WES and amplicon deep sequencing. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "(a) Mutation frequencies of STAT5B, JAK3 and GNAI2 correlating to CD8 dimer and TCR type. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "Distribution of mutations in ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "(b) STAT5B, ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "(c) JAK3 and ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "(d) GNAI2 genes. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "The frequency of each alteration is denoted within parentheses after its label. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "Filled circles indicate known mutation hotspots and empty circles mutations with unknown functional consequence. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "*A total of four nonsynonymous missense mutations identified resulting in the change of two amino acids. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "G, GTP-binding; ND, not done; SH2, Src Homology 2; TA, transcriptional activation domain; TCR, T-cell receptor. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "these cascades were also altered indicating the importance of GNAI2, JAK3 and STAT5B mutations described above. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "These include the role of JAK1 and JAK3 in \u03b3c cytokine signaling, Oncostatin M signaling, interleukin-2 and interleukin-9 signaling, cAMPmediated signaling and G\u03b1 i signaling. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "Molecular mechanisms of cancer was also found enriched, suggesting the involvement of classical cancer genes in this disease. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "The latter is supported by the finding of at least one mutated tumor suppressor or oncogene in each case (Supplementary Table 5). ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 120,
                    "end": 127,
                    "type": "table",
                    "text": "Table 5"
                }
            ]
        },
        {
            "text": "Because IPA does not consider recurrence of gene alterations, we repeated the analysis with the list of recurrently mutated genes only. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "Importantly, all the above pathways, except G\u03b1 i signaling, were found significantly enriched in EITL (Supplementary Table 15).",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 117,
                    "end": 125,
                    "type": "table",
                    "text": "Table 15"
                }
            ]
        },
        {
            "text": "To verify the above by an unrelated approach, we performed gene expression profiling of four EITL tumors, two of CD8\u03b1\u03b1 and two of CD8\u03b1\u03b2 origin. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "As EITL is suggested to arise from CD8+ IELs, 13 we integrated our data with publicly available profile of CD8\u03b1\u03b1 and CD8\u03b1\u03b2 T-cells from healthy donors. ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 46,
                    "end": 48,
                    "type": "bibr",
                    "ref_id": "b12",
                    "text": "13"
                }
            ]
        },
        {
            "text": "44 There was a total of 1760 genes significantly upregulated in EITL tumors (P o 0.05 and fold change \u2a7e 1.5; Supplementary Table 16). ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b43",
                    "text": "44"
                },
                {
                    "start": 109,
                    "end": 131,
                    "type": "table",
                    "text": "Supplementary Table 16"
                }
            ]
        },
        {
            "text": "GSEA against Molecular Signatures Database gene sets 45 was used to identify deregulated pathways. ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 53,
                    "end": 55,
                    "type": "bibr",
                    "ref_id": "b44",
                    "text": "45"
                }
            ]
        },
        {
            "text": "The used gene sets and all statistics from GSEA are shown in Supplementary Table 17. ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 61,
                    "end": 83,
                    "type": "table",
                    "text": "Supplementary Table 17"
                }
            ]
        },
        {
            "text": "It is noteworthy that GSEA independently confirmed the findings of IPA analysis using mutated genes from WES. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "Several aspects of GPCR signaling were found significantly enriched in EITL samples including GPCR ligand binding, signaling by GPCR and, importantly, G\u03b1 i signaling ( Supplementary Figure 8). ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 168,
                    "end": 191,
                    "type": "figure",
                    "text": "Supplementary Figure 8)"
                }
            ]
        },
        {
            "text": "These clearly suggest a marked deregulation of G\u03b1 i signaling in EITL and further indicate the functional importance of discovered GNAI2 mutations.",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "In addition, we also identified KEGG JAK-STAT signaling pathway as significantly enriched in EITLs. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "The higher side qvalue ( Supplementary Table 17) is in this regard not surprising as the activation of JAK-STAT pathway is known to occur through protein phosphorylation and not increased expression of mRNA. ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 25,
                    "end": 47,
                    "type": "table",
                    "text": "Supplementary Table 17"
                }
            ]
        },
        {
            "text": "More importantly, an outstanding association was identified with genes containing STAT5B binding sites in their promoters, both for the shorter and longer consensus motif. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "We further confirmed this by GSEA against publicly available gene set of STAT5 target genes. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "46 There was a significant enrichment between STAT5 targets and genes upregulated in EITL (normalized enrichment score = 1.78, false discovery rate q-value o 0.001; Supplementary  Figure 8d). ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b45",
                    "text": "46"
                },
                {
                    "start": 165,
                    "end": 189,
                    "type": "figure",
                    "text": "Supplementary  Figure 8d"
                }
            ]
        },
        {
            "text": "Gene expression profiling data was validated by real-time PCR of randomly selected genes (Supplementary Table 18). ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 104,
                    "end": 112,
                    "type": "table",
                    "text": "Table 18"
                }
            ]
        },
        {
            "text": "The values from the two experiments were consistent, although the correlation was not statistically significant because of the small sample size (Supplementary Figure 9). ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 145,
                    "end": 169,
                    "type": "figure",
                    "text": "(Supplementary Figure 9)"
                }
            ]
        },
        {
            "text": "In summary, JAK-STAT and GPCR signaling pathways were demonstrated as significantly enriched in EITL tumors using two different data sets and methodologies.",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "Targeted therapy inhibits viability of primary EITL cells While activating mutations in genes encoding \u03b1-subunits of G proteins occur in many human cancers, oncogenic alterations in the inhibitory subunits of G proteins exist at a much lower frequency. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "34 Oncogenic form of GNAI2 (GNAI2 p.R179C/H), referred to as gip2, 32 was first identified in endocrine tumors of adrenal cortex and ovary, 31 and p.T182A was thereafter also described as a constitutively activated mutant. ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b33",
                    "text": "34"
                },
                {
                    "start": 67,
                    "end": 69,
                    "type": "bibr",
                    "ref_id": "b31",
                    "text": "32"
                },
                {
                    "start": 140,
                    "end": 142,
                    "type": "bibr",
                    "ref_id": "b30",
                    "text": "31"
                }
            ]
        },
        {
            "text": "33 Notably, gip2 was demonstrated to constitutively activate mitogen-activated protein kinase, 47 likely through inhibitory effect on intracellular cAMP levels. ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b32",
                    "text": "33"
                },
                {
                    "start": 95,
                    "end": 97,
                    "type": "bibr",
                    "ref_id": "b46",
                    "text": "47"
                }
            ]
        },
        {
            "text": "48 To better understand the above, we created stable cell lines overexpressing wild-type and mutant forms (p.R179C and p.R179S) of GNAI2. ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b47",
                    "text": "48"
                }
            ]
        },
        {
            "text": "A strong upregulation of phosphorylated ERK1/2 level was detected in both mutant cells, whereas the total ERK1/2 protein levels remained unchanged (Figure 4a). ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 147,
                    "end": 157,
                    "type": "figure",
                    "ref_id": "fig_2",
                    "text": "(Figure 4a"
                }
            ]
        },
        {
            "text": "The same observation was made in two independent cell lines. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "Consistent with this, immunohistochemical analysis of GNAI2 mutant cases also revealed upregulation of phosphorylated ERK1/2 (Supplementary Table 12), examples of which are shown in Figure 4b, suggesting that the MEK-ERK signaling pathway is aberrantly activated in these EITL tumors.",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 140,
                    "end": 148,
                    "type": "table",
                    "text": "Table 12"
                },
                {
                    "start": 182,
                    "end": 191,
                    "type": "figure",
                    "ref_id": "fig_2",
                    "text": "Figure 4b"
                }
            ]
        },
        {
            "text": "Notably, the identification of activated pathways in EITL offers novel treatment opportunities. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "JAK3 and STAT5B are both directly targetable by small-molecule inhibitors, and because mutant GNAI2 activates the MEK-ERK pathway, MEK inhibitors may be effective for the treatment of EITL. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "To further confirm the involvement of JAK-STAT and GPCR signaling pathways in the survival of EITL, we evaluated the effect of two inhibitors of both pathways in primary EITL cells-Tofacitinib (pan-JAK inhibitor), Stattic (STAT3 inhibitor) and MEK inhibitors Trametinib and PD0325901. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "All four inhibitors reduced cell viability in a dosedependent manner compared with the vehicle-treated control (Figure 4c). ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 111,
                    "end": 122,
                    "type": "figure",
                    "ref_id": "fig_2",
                    "text": "(Figure 4c)"
                }
            ]
        },
        {
            "text": "Importantly, the primary cells were resistant to an inhibitor of a non-relevant pathway, the EGFR inhibitor Gefitinib, suggesting that the observed effect was not because of general cytotoxicity. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "Moreover, all four drugs clearly inhibited the downstream signaling cascades as demonstrated by suppression of STAT3, STAT5 and ERK1/2 phosphorylation (Figure 4d).",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 151,
                    "end": 161,
                    "type": "figure",
                    "ref_id": "fig_2",
                    "text": "(Figure 4d"
                }
            ]
        },
        {
            "text": "These primary EITL cells harbor mutations in both JAK3 and downstream STAT5B, which may explain the inferior sensitivity of Tofacitinib compared with Stattic. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "Further supporting our data, JAK-STAT cascade inactivation either by knockdown of pathway members or targeted therapy also effectively reduces cell viability of cutaneous T-cell lymphoma cells that harbor an activating p. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "A573V JAK3 mutation. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "[49][50][51][52] Despite the lack of GNAI2 mutation in the primary EITL cells, several other members of the GPCR pathway-the GPCRs HTR1F, GRM5, MRGPRX3 and GPR179, and protein tyrosine phosphatase DUSP4 (Supplementary Table 5)are all altered in these cells potentially leading to downstream activation of the GPCR pathway. ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 4,
                    "type": "bibr",
                    "ref_id": "b48",
                    "text": "[49]"
                },
                {
                    "start": 4,
                    "end": 8,
                    "type": "bibr",
                    "ref_id": "b49",
                    "text": "[50]"
                },
                {
                    "start": 8,
                    "end": 12,
                    "type": "bibr",
                    "ref_id": "b50",
                    "text": "[51]"
                },
                {
                    "start": 12,
                    "end": 16,
                    "type": "bibr",
                    "ref_id": "b51",
                    "text": "[52]"
                },
                {
                    "start": 218,
                    "end": 225,
                    "type": "table",
                    "text": "Table 5"
                }
            ]
        },
        {
            "text": "Importantly, DUSP4 is known to inactivate ERK1/2. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "53 The p.R300W mutation identified in the primary EITL cells is positioned right in the middle of DUSP4 catalytic dual-specificity phosphatase domain. ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 0,
                    "end": 2,
                    "type": "bibr",
                    "ref_id": "b52",
                    "text": "53"
                }
            ]
        },
        {
            "text": "As commonly observed for mutations within the functional domains of enzymes, it is likely that the identified p.R300W mutation causes inactivation of the DUSP4 protein that leads to the activation of ERK proteins and might explain the effectiveness of MEK inhibition in these cells. ",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "In addition, GPCR, G\u03b1 i and MEK-ERK pathways are all significantly enriched in the original tumor sample ( Supplementary Figures 8a and c), further supporting the aberrant activation of these signaling pathways. ",
            "section": "Copy number alterations in EITL",
            "ref_spans": [
                {
                    "start": 107,
                    "end": 138,
                    "type": "figure",
                    "text": "Supplementary Figures 8a and c)"
                }
            ]
        },
        {
            "text": "Taken together, these results indicate that targeted therapy may be useful in the treatment of EITL patients.",
            "section": "Copy number alterations in EITL"
        },
        {
            "text": "This is the first study to characterize comprehensively the molecular changes in EITL and provides novel insights into the pathogenesis of this disease. ",
            "section": "CONCLUSIONS"
        },
        {
            "text": "We have clearly demonstrated alterations in the JAK-STAT and GPCR signaling pathways on multiple levels, including mutations, chromosomal alterations and transcriptional upregulation. ",
            "section": "CONCLUSIONS"
        },
        {
            "text": "The high mutation frequency and location of mutations in key functional domains indicate the importance of these variants and notably may present novel opportunities for targeted therapies or better diagnostics. ",
            "section": "CONCLUSIONS"
        },
        {
            "text": "This is supported by our in vitro data demonstrating response of primary EITL cells to inhibitors of both pathways. ",
            "section": "CONCLUSIONS"
        },
        {
            "text": "Further studies are required to support these findings and to functionally evaluate them in a disease-specific model.",
            "section": "CONCLUSIONS"
        },
        {
            "text": "The authors declare no conflict of interest.",
            "section": "CONFLICT OF INTEREST"
        }
    ]
}